Minerva Neurosciences (NERV) Debt to Equity (2013 - 2017)

Minerva Neurosciences has reported Debt to Equity for 5 years, with the latest figure at $0.01 in Q2 2017.

• For the quarter ending Q2 2017, Debt to Equity fell 73.79% year-over-year to $0.01; the trailing twelve-month figure through Jun 2017 stood at $0.01 (down 73.79% YoY), and the FY2016 full-year result was $0.04, down 76.42% from the prior year.
• Debt to Equity for Q2 2017 stood at $0.01, down from $0.02 in the prior quarter.
• The five-year high for Debt to Equity was $0.15 in Q4 2015, with the low at $0.0 in Q4 2013.
• Historically, Debt to Equity has averaged $0.07 across 5 years, with a median of $0.05 in 2014.
• Annual changes were most pronounced in 2015 — Debt to Equity surged 168.89% — and 2017, when it slumped 77.89%.
• Minerva Neurosciences' Debt to Equity stood at $0.0 in 2013, then jumped by 9357.24% to $0.05 in 2014, then surged by 224.96% to $0.15 in 2015, then sank by 76.42% to $0.04 in 2016, then tumbled by 62.67% to $0.01 in 2017.
• The last three Debt to Equity figures came in at $0.01 (Q2 2017), $0.02 (Q1 2017), and $0.04 (Q4 2016), per Business Quant data.